Strategic partnerships Opportunity to leverage CT PES’s inhalation formulation expertise and spray drying / supercritical precipitation capabilities by targeting respiratory drug developers and CROs/CDMOs seeking specialized particle engineering for early-stage to clinical manufacturing.

Clinical scale readiness CT PES demonstrates end-to-end capabilities from proof-of-concept to Phase III cGMP production, suggesting a sales angle to biotech and pharma companies aiming to accelerate development timelines with integrated CDMO/CRO services.

Award credibility Recent recognition such as the 2025 Most Promising Drug Delivery Technology award can be leveraged to build trust with potential clients seeking innovative particle engineering solutions and differentiated delivery technologies.

Limited headcount agility With a smaller team (11-50 employees) and mid-market revenue, CT PES could benefit from multi-project engagement strategies, preferred partner programs, and scalable service packages to expand capacity without rapid internal hiring.

Growth through collaborations Past collaborations in inhaled niclosamide formulations and NanOlogy venture indicate a pattern of partnering with biotech entities; pursue additional co-development and exclusive supply arrangements to expand pipeline and geographic reach.